L
Lydia Giles
Researcher at University of Pennsylvania
Publications - 12
Citations - 954
Lydia Giles is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Melanoma & Temozolomide. The author has an hindex of 6, co-authored 9 publications receiving 702 citations. Previous affiliations of Lydia Giles include Hospital of the University of Pennsylvania.
Papers
More filters
Journal ArticleDOI
A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma
Alexander C. Huang,Robert J. Orlowski,Robert J. Orlowski,Xiaowei Xu,Rosemarie Mick,Sangeeth M. George,Sangeeth M. George,Patrick Yan,Sasikanth Manne,Adam A. Kraya,Bradley Wubbenhorst,Liza Dorfman,Kurt D'Andrea,Brandon Wenz,Shujing Liu,Lakshmi Chilukuri,Andrew Kozlov,Mary Carberry,Lydia Giles,Melanie W. Kier,Felix Quagliarello,Suzanne McGettigan,Kristin Kreider,Lakshmanan Annamalai,Qing Zhao,Robin Mogg,Wei Xu,Wendy M. Blumenschein,Jennifer H. Yearley,Gerald P. Linette,Ravi K. Amaravadi,Lynn M. Schuchter,Ramin S. Herati,Bertram Bengsch,Bertram Bengsch,Katherine L. Nathanson,Michael D. Farwell,Giorgos C. Karakousis,E. John Wherry,Tara C. Mitchell +39 more
TL;DR: A rapid and potent anti-tumor response was identified, with 8 of 27 patients experiencing a complete or major pathological response after a single dose of anti-PD-1, all of whom remain disease free.
Journal ArticleDOI
Diverse cutaneous side effects associated with BRAF inhibitor therapy: A clinicopathologic study
Emily Y. Chu,Karolyn A. Wanat,Christopher J. Miller,Ravi K. Amaravadi,Leslie A. Fecher,Marcia S. Brose,Suzanne McGettigan,Lydia Giles,Lynn M. Schuchter,John T. Seykora,Misha Rosenbach +10 more
TL;DR: In this paper, the authors evaluated the clinical and histologic feature of skin side effects developing on vemurafenib or dabrafenib therapy in 14 patients and found that eight patients developed one or more squamous cell carcinomas, and 11 patients formed benign verrucous keratoses.
Iconography : Diverse cutaneous side effects associated with BRAF inhibitor therapy: A clinicopathologic study
Emily Y. Chu,Karolyn A. Wanat,Christopher J. Miller,Ravi K. Amaravadi,Leslie A. Fecher,Marcia S. Brose,Suzanne McGettigan,Lydia Giles,Lynn M Schuchter,John T. Seykora,Misha Rosenbach +10 more
TL;DR: Selective BRAF inhibitor therapy is associated with the development of malignant and benign growths, including keratoacanthoma-like squamous cell carcinomas, warty dyskeratomas, and verrucous keratoses, along with widespread eruptions with histologic features of acantholytic Dyskeratosis.
Journal ArticleDOI
Phase II Trial of Temozolomide and Sorafenib in Advanced Melanoma Patients with or without Brain Metastases.
Ravi K. Amaravadi,Lynn M. Schuchter,David F. McDermott,Amy Kramer,Lydia Giles,Kristi Gramlich,Mary Carberry,Andrea B. Troxel,Richard Letrero,Katherine L. Nathanson,Michael B. Atkins,Peter J. O'Dwyer,Keith T. Flaherty +12 more
TL;DR: Temozolomide plus sorafenib was well tolerated and showed activity in melanoma patients without prior history of temozolmide and the activity of this combination regimen warrants further investigation.
Journal ArticleDOI
Updated results of a randomized phase II study comparing two schedules of temozolomide in combination with sorafenib in patients with advanced melanoma
Ravi K. Amaravadi,Lynn M. Schuchter,D. F. McDermott,Amy Kramer,Lydia Giles,Andrea B. Troxel,C. A. Medina,K. L. Nathanson,Peter O'Dwyer,Keith T. Flaherty +9 more
TL;DR: This phase II trial testing sorafenib, an oral Raf kinase/VEGFR2 inhibitor, and temozolomide in pt with metastatic melanoma and prior TEM is to determine the optimal dosing of TEM, response, and toxicity rates.